Treatment of Vasomotor Symptoms

被引:0
|
作者
Atwell, Karina [1 ]
White, Morgan [1 ]
Kuphal, Greta [1 ]
Williams, Makeba [2 ]
Schrager, Sarina [1 ]
机构
[1] Univ Wisconsin, Dept Family Med & Community Hlth, 610 Whitney Way, Madison, WI 53705 USA
[2] Washington Univ, Dept Obstet & Gynecol, St Louis, MO USA
关键词
Menopause; Vasomotor Symptoms; Women's Health; TRANSDERMAL ESTROGEN THERAPY; CIMICIFUGA-RACEMOSA EXTRACT; MENOPAUSAL HORMONE-THERAPY; HOT FLASHES; WOMENS HEALTH; BREAST-CANCER; MANAGEMENT; EFFICACY; RISK; SAFETY;
D O I
10.3122/jabfm.2023.230408R1
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Vasomotor symptoms (VMS) related to the menopausal transition affect the majority of women and contribute to significant quality of life burden. Incidence, length, severity and report of symptoms vary by race, ethnicity, and coexisting health conditions. The pathophysiology of VMS is not fully understood and is likely multifactorial, involving changes in the hypothalamicpituitary-ovarian axis during the menopausal transition. Treatment approaches include lifestyle modifications, hormonal and non-hormonal therapies, including integrative and complementary medicine approaches. Systemic hormone therapy with estrogen is the most effective treatment. Emerging evidence suggests that treatment with SSRIs, SNRIs, and gabapentin is effective for many women who want to avoid hormone therapy. A shared decision approach to treatment decisions involves consideration of risks with treatment options and discussion of patient priorities.
引用
收藏
页码:923 / 932
页数:10
相关论文
共 50 条
  • [21] Modification of vasomotor symptoms after various treatment modalities in the postmenopause
    Carranza-Lira, S
    Cortés-Fuentes, E
    INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS, 2001, 73 (02) : 169 - 171
  • [22] Basics of vasomotor symptoms
    Thurston, Rebecca C.
    MENOPAUSE-THE JOURNAL OF THE MENOPAUSE SOCIETY, 2024, 31 (12): : 1085 - 1086
  • [23] Venlafaxine in the treatment of depressive and vasomotor symptoms in women with perimenopausal depression
    Ladd, CO
    Newport, DJ
    Ragan, KA
    Loughhead, A
    Stowe, ZN
    DEPRESSION AND ANXIETY, 2005, 22 (02) : 94 - 97
  • [24] A Clinical Review on Paroxetine and Emerging Therapies for the Treatment of Vasomotor Symptoms
    David, Paru S.
    Smith, Taryn L.
    Nordhues, Hannah C.
    Kling, Juliana M.
    INTERNATIONAL JOURNAL OF WOMENS HEALTH, 2022, 14 : 353 - 361
  • [25] Treatment of vasomotor symptoms in patients with breast cancer, a narrative review
    Pilnik, Susana
    Gelin, Marina
    De Nardo, Barbara
    Alejandra Belardo, Maria
    REVISTA PERUANA DE GINECOLOGIA Y OBSTETRICIA, 2018, 64 (01): : 69 - 76
  • [26] Pharmacokinetic evaluation of fezolinetant for the treatment of vasomotor symptoms caused by menopause
    Cucinella, Laura
    Tedeschi, Sara
    Memoli, Stefano
    Cassani, Chiara
    Martini, Ellis
    Nappi, Rossella E.
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2025, 21 (02) : 105 - 113
  • [27] Physiology of thermoregulatory dysfunction and current approaches to the treatment of vasomotor symptoms
    Deecher, DC
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2005, 14 (04) : 435 - 448
  • [28] Efficacy and safety of desvenlafaxine succinate for treatment of menopausal vasomotor symptoms
    Gass, Margery
    Olivier, Sophie
    Constantine, Ginger
    OBSTETRICS AND GYNECOLOGY, 2007, 109 (04): : 75S - 75S
  • [29] Recent Advances in the Treatment of Vasomotor Symptoms-Nonhormonal Therapies
    Reed, Susan D.
    MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2020, 27 (12): : 1448 - 1449
  • [30] Vasomotor symptoms in the perimenopause
    Kronenberg, F
    PERIMENOPAUSE, 1997, : 184 - 201